Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma

Xu-Monette, Zijun Y; Deng, Qipan; Manyam, Ganiraju C; Tzankov, Alexander; Ling, Li; Xia, Yi; Wang, Xiao-Xiao; Zou, Dehui; Visco, Carlo; Dybkær, Karen; Jun, Li; Zhang, Li; Liang, Han; Montes-Moreno, Santiago; Chiu, April; Orazi, Attilio; Youli, Zu; Bhagat, Govind; Richards, Kristy L; Hsi, Eric D; Choi, William W L; van Krieken, J Han; Huh, Jooryung; Ponzoni, Maurilio; Ferreri, Andrés J M; Parsons, Ben M; Møller, Michael B; Wang, Sa A; Miranda, Roberto N; Piris, Miguel A; Winter, Jane N; Medeiros, L Jeffrey; Yong, Li; Young, Ken H

doi:10.1158/1078-0432.CCR-15-2296

MYC is a critical driver oncogene in many cancers, and its deregulation in the forms of translocation and overexpression has been implicated in lymphomagenesis and progression of diffuse large B-cell lymphoma (DLBCL). The MYC mutational profile and its roles in DLBCL are unknown. This study aims to determine the spectrum of MYC mutations in a large group of patients with DLBCL, and to evaluate the clinical significance of MYC mutations in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy.

Titolo:	Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma
Autori:	Xu-Monette, Zijun Y Deng, Qipan Manyam, Ganiraju C Tzankov, Alexander Li, Ling Xia, Yi Wang, Xiao-Xiao Zou, Dehui VISCO, Carlo Dybkær, Karen Li, Jun Zhang, Li Liang, Han Montes-Moreno, Santiago Chiu, April Orazi, Attilio Zu, Youli Bhagat, Govind Richards, Kristy L Hsi, Eric D Choi, William W L van Krieken, J Han Huh, Jooryung Ponzoni, Maurilio Ferreri, Andrés J M Parsons, Ben M Møller, Michael B Wang, Sa A Miranda, Roberto N Piris, Miguel A Winter, Jane N Medeiros, L Jeffrey Li, Yong Young, Ken H mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2016
Rivista:	CLINICAL CANCER RESEARCH
Abstract:	MYC is a critical driver oncogene in many cancers, and its deregulation in the forms of translocation and overexpression has been implicated in lymphomagenesis and progression of diffuse large B-cell lymphoma (DLBCL). The MYC mutational profile and its roles in DLBCL are unknown. This study aims to determine the spectrum of MYC mutations in a large group of patients with DLBCL, and to evaluate the clinical significance of MYC mutations in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy.
Handle:	http://hdl.handle.net/11562/993663
Appare nelle tipologie:	01.01 Articolo in Rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11562/993663

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

CATALOGO DEI PRODOTTI DELLA RICERCA

File in questo prodotto: